UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
Media Contact Evoke
Canale Katherine SmithKatherine.email@example.com Investor Contact LifeSci Advisors, LLC Joyce Allairejallaire@lifesciadvisors.com
Source: Unity Biotechnology, Inc.